Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
BRAF V600E-mutant Metastatic Colorectal Cancer
Conditions
BRAF V600E-mutant Metastatic Colorectal Cancer
Trial Timeline
Oct 13, 2016 → Nov 10, 2022
NCT ID
NCT02928224About Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil
Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil is a phase 3 stage product being developed by Ono Pharmaceutical for BRAF V600E-mutant Metastatic Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02928224. Target conditions include BRAF V600E-mutant Metastatic Colorectal Cancer.
What happened to similar drugs?
0 of 1 similar drugs in BRAF V600E-mutant Metastatic Colorectal Cancer were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02928224 | Phase 3 | Completed |
Competing Products
13 competing products in BRAF V600E-mutant Metastatic Colorectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 21 |
| TMZ + E7016 | Eisai | Phase 2 | 27 |
| encorafenib + Binimetinib + Cetuximab | Ono Pharmaceutical | Phase 2 | 35 |
| Encorafenib + Cetuximab + FOLFIRI | Merck | Phase 2 | 35 |
| Tafinlar/Mekinist | Novartis | Pre-clinical | 33 |
| BKM120 Combined with Vemurafenib (PLX4032) | Novartis | Phase 1/2 | 32 |
| Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab | Novartis | Phase 1 | 21 |
| Cobimetinib + Atezolizumab + Pembrolizumab | Roche | Phase 3 | 32 |
| LGX818 + MEK162 + LEE011 | Pfizer | Phase 1/2 | 32 |
| MEK162 | Pfizer | Phase 2 | 35 |
| Encorafenib + Binimetinib + cemiplimab+fianlimab | Regeneron Pharmaceuticals | Phase 2 | 42 |
| Plixorafenib + Cobicistat 150 MG [Tybost] | Brain Biotech | Phase 1 | 26 |
| Dabrafenib + Trametinib + Hydroxychloroquine | Brain Biotech | Phase 1/2 | 26 |